Anaptysbio FY 2022: revenue $10.3M, down 84%; diluted EPS −$4.57

Key figures from this report

These are the numbers Anaptysbio reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$10.3M−84% from $63.2M in FY 202110-K income statement, on EDGAR
2. Net income−$128.7MAgainst −$57.8M in FY 202110-K income statement, on EDGAR
3. Diluted EPS−$4.57Against −$2.11 in FY 202110-K income statement, on EDGAR
4. Cash and cash equivalents$71.3M−86% from $495.7M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations−$73.6MAgainst −$45.9M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables